FcRN receptor antagonists in the management of myasthenia gravis
Myasthenia gravis (MG) is an autoimmune disorder characterized by autoantibodies specifically directed against proteins located within the postsynaptic membrane of the neuromuscular junction. These pathogenic autoantibodies can be reduced by therapies such as plasma exchange, IVIG infusions and othe...
Main Authors: | Vinaya Bhandari, Vera Bril |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1229112/full |
Similar Items
-
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
by: James F. Howard, et al.
Published: (2024-01-01) -
Megalin Orchestrates FcRn Endocytosis and Trafficking
by: Eileen Dahlke, et al.
Published: (2022-12-01) -
The contribution of cell surface FcRn in monoclonal antibody serum uptake from the intestine in suckling rat pups
by: Philip R Cooper, et al.
Published: (2014-10-01) -
Fully human monoclonal antibody inhibitors of the neonatal Fc receptor (FcRn) reduce circulating IgG in nonhuman primates
by: Andrew E Nixon, et al.
Published: (2015-04-01) -
Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro
by: Omar S. Qureshi, et al.
Published: (2024-12-01)